Based on the current IDSA/ATS guidelines and recent trials, including CONVERT, what do you see as the most important advances in our understanding of NTM pulmonary disease, in particular, with respect to refractory MAC lung disease?

Based on the current IDSA/ATS guidelines and recent trials, including CONVERT, what do you see as the most important advances in our understanding of NTM pulmonary disease, in particular, with respect to refractory MAC lung disease?

CLICK HERE FOR CME CREDIT

Based on the current IDSA/ATS guidelines and recent trials, including CONVERT, what do you see as the most important advances in our understanding of NTM pulmonary disease, in particular, with respect to refractory MAC lung disease?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Julie Philley, MD

Julie Philley, MD

Chair of the Department of Medicine
Chief of Pulmonary and Critical Care
UT Health North Campus Tyler
The University of Texas Health Sciences Center
Houston, Texas